Aripiprazole oral soluble film - CMG Pharmaceutical

Drug Profile

Aripiprazole oral soluble film - CMG Pharmaceutical

Alternative Names: Aripiprazole - CMG Pharmaceutical

Latest Information Update: 07 Apr 2016

Price : $50

At a glance

  • Originator CMG Pharmaceutical
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Chlorobenzenes; Mood stabilisers; Piperazines; Quinolines; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor antagonists; Dopamine D4 receptor antagonists; Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists; Serotonin 2C receptor agonists; Serotonin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Schizophrenia

Most Recent Events

  • 01 Mar 2016 CMG Pharmaceutical completes a phase I trial in Schizophrenia in Canada, USA (PO) (NCT02501109)
  • 01 Oct 2015 Phase-I clinical trials in Schizophrenia in Canada, USA (PO) (NCT02501109)
  • 04 Jun 2015 CMG Pharmaceutical plans a phase I trial for Schizophrenia in USA and Canada (NCT02501109)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top